Healthcare provider profile · identity verified

Daniel David Sacolick, MD

Internal Medicine · HEWLETT, NY · NPI 1386713055

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	977	306
Atorvastatin Calcium	Atorvastatin Calcium	689	214
Amlodipine Besylate	Amlodipine Besylate	634	194
Losartan Potassium	Losartan Potassium	401	122
Levothyroxine Sodium	Levothyroxine Sodium	302	97
Metoprolol Succinate	Metoprolol Succinate	264	79
Escitalopram Oxalate	Escitalopram Oxalate	197	64
Alprazolam	Alprazolam	188	57
Ezetimibe	Ezetimibe	146	51
Metformin Hcl	Metformin Hcl	140	46
Metformin Hcl Er	Metformin Hcl	136	44
Zolpidem Tartrate	Zolpidem Tartrate	134	34
Sertraline Hcl	Sertraline Hcl	132	51
Hydrochlorothiazide	Hydrochlorothiazide	127	43
Lisinopril	Lisinopril	124	39
Omeprazole	Omeprazole	108	35
Simvastatin	Simvastatin	89	28
Pantoprazole Sodium	Pantoprazole Sodium	86	24
Allopurinol	Allopurinol	75	22
Furosemide	Furosemide	75	27
Famotidine	Famotidine	73	20
Tamsulosin Hcl	Tamsulosin Hcl	73	23
Eliquis	Apixaban	69	25
Synthroid	Levothyroxine Sodium	69	20
Fluticasone Propionate	Fluticasone Propionate	64	21
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	63	23
Trazodone Hcl	Trazodone Hcl	63	18
Finasteride	Finasteride	60	14
Duloxetine Hcl	Duloxetine Hcl	56	14
Montelukast Sodium	Montelukast Sodium	51	13
Atenolol	Atenolol	50	19
Clonazepam	Clonazepam	49	20
Metoprolol Tartrate	Metoprolol Tartrate	49	20
Pravastatin Sodium	Pravastatin Sodium	49	18
Clopidogrel	Clopidogrel Bisulfate	47	13
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	44	suppressed
Nebivolol Hcl	Nebivolol Hcl	40	15
Gabapentin	Gabapentin	39	18
Lorazepam	Lorazepam	39	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	37	13
Olmesartan Medoxomil	Olmesartan Medoxomil	37	suppressed
Irbesartan	Irbesartan	35	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	35	35
Valsartan	Valsartan	35	suppressed
Ozempic	Semaglutide	34	11
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	33	26
Potassium Chloride	Potassium Chloride	33	12
Carvedilol	Carvedilol	32	suppressed
Nifedipine Er	Nifedipine	30	suppressed
Enalapril Maleate	Enalapril Maleate	28	suppressed
Bupropion Xl	Bupropion Hcl	27	suppressed
Diazepam	Diazepam	27	suppressed
Ramipril	Ramipril	27	suppressed
Xarelto	Rivaroxaban	26	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	24	suppressed
Januvia	Sitagliptin Phosphate	22	suppressed
Temazepam	Temazepam	22	suppressed
Hydralazine Hcl	Hydralazine Hcl	20	suppressed
Jardiance	Empagliflozin	20	11
Spironolactone	Spironolactone	20	suppressed
Telmisartan	Telmisartan	19	suppressed
Alendronate Sodium	Alendronate Sodium	18	suppressed
Glimepiride	Glimepiride	18	suppressed
Meloxicam	Meloxicam	18	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Mounjaro	Tirzepatide	18	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	17	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	16	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	16	suppressed
Citalopram Hbr	Citalopram Hydrobromide	14	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	14	suppressed
Edarbi	Azilsartan Medoxomil	14	suppressed
Azithromycin	Azithromycin	13	12
Farxiga	Dapagliflozin Propanediol	13	suppressed
Naloxone Hcl	Naloxone Hcl	13	suppressed
Raloxifene Hcl	Raloxifene Hcl	13	suppressed
Fenofibrate	Fenofibrate,micronized	12	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	12	suppressed
Klayesta	Nystatin	12	suppressed
Latanoprost	Latanoprost	12	suppressed
Midodrine Hcl	Midodrine Hcl	12	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Potassium Citrate Er	Potassium Citrate	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error